secwatch / observer

8-K filed May 7, 2025, 7:59 PM ET ticker MCRB CIK 0001609809

other material confidence high sentiment neutral materiality 0.75

Seres Q1 net income $32.7M; SER-155 Phase 2 protocol to FDA in weeks

Seres Therapeutics, Inc.

Net income from continuing ops of $32.7M vs net loss of $32.9M YoY, driven by $50M Nestlé installment.
R&D expense down to $11.8M from $19.5M; G&A down to $11.9M from $14.9M.
Cash $58.8M at Mar 31, plus $25M Nestlé installment expected July 2025; runway into Q1 2026.
Plans SER-155 Phase 2 study (248 patients, adaptive design) with interim analysis within 12 months of start.
Regained Nasdaq compliance after 1-for-20 reverse stock split on April 21, 2025.

item 2.02 item 7.01 item 9.01

Machine-readable event card

schema_version: secwatch.filing_event.v1
accession: 0001193125-25-114430
form_type: 8-K
ticker: MCRB
cik: 0001609809
company_name: Seres Therapeutics, Inc.
filed_at: 2025-05-07T23:59:59+00:00
discovered_at: 2026-05-14T18:02:49.009368+00:00
generated_at: 2026-05-22T08:12:01.239607+00:00
sec_items: ["2.02", "7.01", "9.01"]
event_type: other_material
sentiment: neutral
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: high
secwatch_canonical_url: https://secwatch.observer/filing/0001193125-25-114430
json_url: https://secwatch.observer/filing/0001193125-25-114430.json
markdown_url: https://secwatch.observer/filing/0001193125-25-114430.md
text_url: https://secwatch.observer/filing/0001193125-25-114430.txt
edgar_index_url: https://www.sec.gov/Archives/edgar/data/1609809/000119312525114430/0001193125-25-114430-index.htm
edgar_primary_document_url: https://www.sec.gov/Archives/edgar/data/1609809/000119312525114430/d915177d8k.htm
generated_by_model: deepseek-v4-flash:cloud@v2
review_status: machine_generated
human_reviewed: false
corrected: false
correction_note: null
correction_timestamp: null
superseded_by: null

JSON Markdown Plain text

Comparable filings

KRMN

Selling stockholders price upsized secondary offering of 14M shares at $61/share for ~$854M gross proceeds

Karman Holdings Inc. June 1, 2026, 5:28 PM ET other_material Items 1.01, 7.01, 8.01, 9.01

same SEC item: 7.01, 9.01 same event type: other_material similar materiality

Filing page SEC filing

TRTX

TRTX posts 1Q26 distributable earnings $0.25/sh, book value $11.06, loan portfolio $4.3B

TPG RE Finance Trust, Inc. June 1, 2026, 5:23 PM ET other_material Items 7.01, 9.01

same SEC item: 7.01, 9.01 same event type: other_material similar materiality

Filing page SEC filing

AIB

Blockchain Digital signs 15-yr, 65 MW electric agreement at CLT-01; 25 MW LOIs in pipeline

BlockchAIn Digital Infrastructure, Inc. June 1, 2026, 4:57 PM ET other_material Items 1.01, 7.01, 9.01

same SEC item: 7.01, 9.01 same event type: other_material similar materiality

Filing page SEC filing

AII

American Integrity fully places 2026-2027 CAT XOL reinsurance with $2.99B total limit

American Integrity Insurance Group, Inc. June 1, 2026, 4:31 PM ET other_material Items 7.01, 9.01

same SEC item: 7.01, 9.01 same event type: other_material similar materiality

Filing page SEC filing

CSR

Centerspace approves $240-245M asset sales; exits Bismarck and Rapid City

CENTERSPACE June 1, 2026, 4:30 PM ET other_material Items 7.01, 8.01, 9.01

same SEC item: 7.01, 9.01 same event type: other_material similar materiality

Filing page SEC filing

Mid-America Apartments, L.P.

MAA May 2026 blended rents highest in 2 years; repurchased $50M shares

Mid-America Apartments, L.P. June 1, 2026, 4:20 PM ET other_material Items 7.01, 9.01

same SEC item: 7.01, 9.01 same event type: other_material similar materiality

Filing page SEC filing

Liberty Global names Stephen van Rooyen as Ziggo Group CEO; plans Amsterdam listing in 2027

Liberty Global Ltd. June 1, 2026, 4:07 PM ET other_material Items 7.01, 9.01

same SEC item: 7.01, 9.01 same event type: other_material similar materiality

Filing page SEC filing

IDYA

IDEAYA's darovasertib combo meets primary endpoint in Phase 2/3 OptimUM-02 trial for metastatic uveal melanoma

IDEAYA Biosciences, Inc. June 1, 2026, 4:05 PM ET other_material Items 7.01, 8.01, 9.01

same SEC item: 7.01, 9.01 same event type: other_material similar materiality

Filing page SEC filing

Source: SEC EDGAR

accession 0001193125-25-114430

view filing index on sec.gov

view primary document

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.